<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943826</url>
  </required_header>
  <id_info>
    <org_study_id>BO21990</org_study_id>
    <secondary_id>2008-006146-26</secondary_id>
    <nct_id>NCT00943826</nct_id>
  </id_info>
  <brief_title>A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2 arm study investigated the efficacy and safety of the addition of bevacizumab
      (Avastin®) to the current standard of care (multimodality therapy of concurrent radiotherapy
      plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of
      care alone. Patients were randomly assigned to either the Avastin® (10 mg/kg iv q2w) or the
      placebo arm, in combination with radiation therapy (total dose 60 Gy, administered as 2 Gy
      fractions, 5 days/week)plus temozolomide (75 mg/m2 po daily) for 6 weeks. After a 4 week
      treatment break, patients continued to receive Avastin® (10 mg/kg iv q2w) or placebo, plus
      temozolomide (150-200 mg/m2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of
      maintenance treatment. Following the maintenance phase, Avastin® (15 mg/kg iv q3w) or
      placebo monotherapy was continued. The anticipated time on study treatment was until disease
      progression/unacceptable toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator</measure>
    <time_frame>Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)]</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS was defined as the time from randomization to disease progression or death due to any cause.
Disease progression (PD) was assessed by the investigator using adapted Macdonald response criteria (modified World Health Organization (WHO) criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging (MRI) scans, neurological assessment and changes in corticosteroid use.
PD was determined as ≥ 25% increase in the sum of the products of the perpendicular longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir) during the study or unequivocal progression of existing non-index lesions (non-enhancing and enhancing, non-measurable) or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) with no need for a confirmatory scan.
Data from the final analysis is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary: Overall Survival (OS)</measure>
    <time_frame>Randomization until Overall Survival Event</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Survival was defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by an Independent Review Facility</measure>
    <time_frame>Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)]</time_frame>
    <safety_issue>No</safety_issue>
    <description>An Independent Review Facility reviewed the magnetic resonance imaging (MRI) scans used by the investigator to evaluate radiological tumor response. PFS was defined as the time from randomization to disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One-Year Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants who are still alive 1 year post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Two-year Survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants who are still alive 2 years post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stable/Improved Health Related Quality of Life (HRQoL) Using the European Organisation for Research and Treatment of Cancer Scales (EORTC) QLQ-C30 and BN20</measure>
    <time_frame>Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stable and Improved HRQoL during PFS time was determined using the EORTC QLQ-C30 and BN20 questionnaires. The EORTC QLQ-C30 is a 30-item self-reported questionnaire in 5 functional scales (physical,role,emotional,cognitive,social), 3 symptoms scales, 6 single-item measures and a global health status/QoL scale.Patients rated the items on a 4-point scale: 1=not at all to 4=very much.Global health status/QoL items were rated on a 7-point scale: 1=very poor to 7=excellent. The BN20 consisted of 20 questions in 4 scales(future uncertainty,visual disorder,motor dysfunction,communication deficit) and 7 single-item measures rated on a 4-point scale: 1=not at all to 4=very much. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. Stable HRQoL was defined as a change from baseline within 10 points.Improved HRQoL is defined as an increase of at least 10 points for functioning/global health status and a decrease of at least 10 points for symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Serious Adverse Events and Death</measure>
    <time_frame>Until data cutoff= 31 March 2012 (up to 34 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">921</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + RT+Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Concurrent Phase participants received radiotherapy (RT) in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + RT+ Temozolomide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab [Avastin®]</intervention_name>
    <description>10 mg/kg intravenously every 2 weeks in the Concurrent and Maintenance Phases. 15 mg/kg intravenously every 3 weeks in the Monotherapy Phase.</description>
    <arm_group_label>Bevacizumab + RT+Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenously every 2 weeks in the Concurrent and Maintenance Phases and every 3 weeks in the Monotherapy Phase.</description>
    <arm_group_label>Placebo + RT+ Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>75 mg/m2 once daily for 6 weeks, followed by 150-200 mg/m2 once daily on days 1-5 of each 6 x 4 week cycle.</description>
    <arm_group_label>Bevacizumab + RT+Temozolomide</arm_group_label>
    <arm_group_label>Placebo + RT+ Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks</description>
    <arm_group_label>Bevacizumab + RT+Temozolomide</arm_group_label>
    <arm_group_label>Placebo + RT+ Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;

          -  newly diagnosed glioblastoma;

          -  World Health Organization (WHO) performance status &lt;=2;

          -  stable or decreasing corticosteroid dose within 5 days prior to randomization.

        Exclusion Criteria:

          -  evidence of recent hemorrhage or postoperative magnetic resonance imaging (MRI) of
             brain;

          -  any prior chemotherapy or immunotherapy for glioblastomas and low grade astrocytomas;

          -  any prior radiotherapy to brain;

          -  clinically significant cardiovascular disease;

          -  history of &gt;=grade 2 hemoptysis within 1 month prior to randomization;

          -  previous centralized screening for Methylguanine-DNA methyltransferase (MGMT) status
             for enrollment into a clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>North Carolina</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Adelaide</city>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Velen</city>
        <zip>46342</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Forli</city>
        <zip>47023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-si</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hwasun</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-170</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>100</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>194175</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merseyside</city>
        <zip>CH63 45Y</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Romford</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 25, 2015</lastchanged_date>
  <firstreceived_date>July 17, 2009</firstreceived_date>
  <firstreceived_results_date>March 29, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + RT+Temozolomide</title>
          <description>In the Concurrent Phase participants received radiotherapy (RT) in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + RT+Temozolomide</title>
          <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression//unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Concurrent Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="458"/>
                <participants group_id="P2" count="463"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Randomized Treatment</title>
              <participants_list>
                <participants group_id="P1" count="452"/>
                <participants group_id="P2" count="459"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
                <participants group_id="P2" count="421"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment/Did not cooperate</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment/Did not cooperate</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Monotherapy Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment/ Did not cooperate</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + RT+Temozolomide</title>
          <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + RT+Temozolomide</title>
          <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="458"/>
                <measurement group_id="B2" value="463"/>
                <measurement group_id="B3" value="921"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55.9" lower_limit="20" upper_limit="84"/>
                <measurement group_id="B2" value="55.9" lower_limit="18" upper_limit="79"/>
                <measurement group_id="B3" value="55.9" lower_limit="18" upper_limit="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="176"/>
                <measurement group_id="B2" value="165"/>
                <measurement group_id="B3" value="341"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="282"/>
                <measurement group_id="B2" value="298"/>
                <measurement group_id="B3" value="580"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator</title>
        <description>PFS was defined as the time from randomization to disease progression or death due to any cause.
Disease progression (PD) was assessed by the investigator using adapted Macdonald response criteria (modified World Health Organization (WHO) criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging (MRI) scans, neurological assessment and changes in corticosteroid use.
PD was determined as ≥ 25% increase in the sum of the products of the perpendicular longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir) during the study or unequivocal progression of existing non-index lesions (non-enhancing and enhancing, non-measurable) or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) with no need for a confirmatory scan.
Data from the final analysis is presented.</description>
        <time_frame>Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)]</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="458"/>
                  <measurement group_id="O2" value="463"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator</title>
            <description>PFS was defined as the time from randomization to disease progression or death due to any cause.
Disease progression (PD) was assessed by the investigator using adapted Macdonald response criteria (modified World Health Organization (WHO) criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging (MRI) scans, neurological assessment and changes in corticosteroid use.
PD was determined as ≥ 25% increase in the sum of the products of the perpendicular longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir) during the study or unequivocal progression of existing non-index lesions (non-enhancing and enhancing, non-measurable) or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) with no need for a confirmatory scan.
Data from the final analysis is presented.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.6" lower_limit="10.0" upper_limit="11.4"/>
                  <measurement group_id="O2" value="6.2" lower_limit="6.0" upper_limit="7.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Stratified by Region and Recursive partitioning analysis (RPA) Class</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>Stratified by Region and RPA Class.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary: Overall Survival (OS)</title>
        <description>Overall Survival was defined as the time from randomization to death due to any cause.</description>
        <time_frame>Randomization until Overall Survival Event</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>02/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) as Assessed by an Independent Review Facility</title>
        <description>An Independent Review Facility reviewed the magnetic resonance imaging (MRI) scans used by the investigator to evaluate radiological tumor response. PFS was defined as the time from randomization to disease progression or death due to any cause.</description>
        <time_frame>Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)]</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="458"/>
                  <measurement group_id="O2" value="463"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression-free Survival (PFS) as Assessed by an Independent Review Facility</title>
            <description>An Independent Review Facility reviewed the magnetic resonance imaging (MRI) scans used by the investigator to evaluate radiological tumor response. PFS was defined as the time from randomization to disease progression or death due to any cause.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.4" lower_limit="7.9" upper_limit="9.7"/>
                  <measurement group_id="O2" value="4.3" lower_limit="4.1" upper_limit="5.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Stratified by Region and RPA Class.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
            <estimate_desc>Stratified by Region and RPA Class.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One-Year Survival</title>
        <description>Percentage of participants who are still alive 1 year post randomization.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat participants included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="458"/>
                  <measurement group_id="O2" value="463"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With One-Year Survival</title>
            <description>Percentage of participants who are still alive 1 year post randomization.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Two-year Survival</title>
        <description>Percentage of participants who are still alive 2 years post randomization.</description>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>02/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Stable/Improved Health Related Quality of Life (HRQoL) Using the European Organisation for Research and Treatment of Cancer Scales (EORTC) QLQ-C30 and BN20</title>
        <description>Stable and Improved HRQoL during PFS time was determined using the EORTC QLQ-C30 and BN20 questionnaires. The EORTC QLQ-C30 is a 30-item self-reported questionnaire in 5 functional scales (physical,role,emotional,cognitive,social), 3 symptoms scales, 6 single-item measures and a global health status/QoL scale.Patients rated the items on a 4-point scale: 1=not at all to 4=very much.Global health status/QoL items were rated on a 7-point scale: 1=very poor to 7=excellent. The BN20 consisted of 20 questions in 4 scales(future uncertainty,visual disorder,motor dysfunction,communication deficit) and 7 single-item measures rated on a 4-point scale: 1=not at all to 4=very much. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. Stable HRQoL was defined as a change from baseline within 10 points.Improved HRQoL is defined as an increase of at least 10 points for functioning/global health status and a decrease of at least 10 points for symptoms.</description>
        <time_frame>Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)]</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="458"/>
                  <measurement group_id="O2" value="463"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Stable/Improved Health Related Quality of Life (HRQoL) Using the European Organisation for Research and Treatment of Cancer Scales (EORTC) QLQ-C30 and BN20</title>
            <description>Stable and Improved HRQoL during PFS time was determined using the EORTC QLQ-C30 and BN20 questionnaires. The EORTC QLQ-C30 is a 30-item self-reported questionnaire in 5 functional scales (physical,role,emotional,cognitive,social), 3 symptoms scales, 6 single-item measures and a global health status/QoL scale.Patients rated the items on a 4-point scale: 1=not at all to 4=very much.Global health status/QoL items were rated on a 7-point scale: 1=very poor to 7=excellent. The BN20 consisted of 20 questions in 4 scales(future uncertainty,visual disorder,motor dysfunction,communication deficit) and 7 single-item measures rated on a 4-point scale: 1=not at all to 4=very much. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. Stable HRQoL was defined as a change from baseline within 10 points.Improved HRQoL is defined as an increase of at least 10 points for functioning/global health status and a decrease of at least 10 points for symptoms.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Global health status</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="0" upper_limit="26"/>
                  <measurement group_id="O2" value="4" lower_limit="1" upper_limit="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical functioning</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7" lower_limit="0" upper_limit="27"/>
                  <measurement group_id="O2" value="5" lower_limit="1" upper_limit="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social functioning</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="0" upper_limit="26"/>
                  <measurement group_id="O2" value="4" lower_limit="0" upper_limit="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Motor dysfunction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7" lower_limit="1" upper_limit="27"/>
                  <measurement group_id="O2" value="4" lower_limit="0" upper_limit="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Communication deficit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="0" upper_limit="27"/>
                  <measurement group_id="O2" value="4" lower_limit="1" upper_limit="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Serious Adverse Events and Death</title>
        <description>An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>Until data cutoff= 31 March 2012 (up to 34 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population included all randomized participants who received study treatment during the study treatment period. Twelve of the patients randomized to the Placebo + RT + Temozolomide arm received at least one dose of bevacizumab and were added to the Bevacizumab + RT + Temozolomide arm for Safety.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + RT+Temozolomide</title>
            <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="464"/>
                  <measurement group_id="O2" value="447"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adverse Events, Serious Adverse Events and Death</title>
            <description>An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Adverse Events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="455"/>
                  <measurement group_id="O2" value="428"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serious Adverse Events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="170"/>
                  <measurement group_id="O2" value="115"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                  <measurement group_id="O2" value="253"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Population included all randomized participants who received study treatment during the study treatment period. Twelve of the patients randomized to the Placebo + RT + Temozolomide arm received at least one dose of bevacizumab and were added to the Bevacizumab + RT + Temozolomide arm for Safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + RT+Temozolomide</title>
          <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + RT+Temozolomide</title>
          <description>In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Central nervous system abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="438" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="409" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="447"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="447"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche or Genentech, Inc.</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
